Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 98
Price: $ 3500


GlobalData, the Industry analysis specialist, has released its new report, “Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information on the global growth hormone deficiency therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global growth hormone deficiency therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global growth hormone deficiency sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global GHD therapeutics market values $1,354.5m in 2010, after increasing at a Compound Annual Growth Rate (CAGR) of 4.0% during 2005–2010. However, the market is expected to record a CAGR of 3.7% from 2010–2018, to value $1,804.7m by 2018. The growth recorded in GHD therapeutics market during 2005-2010, was primarily attributed to increase in the annual cost of therapy with the existing treatment options available. Apart from this, there are limited numbers of biosimilars formulation such as Omnitrope (somatropin), Valtropin (somatropin) in GHD therapeutics market. The launches of biosimilars have modest impact on the GHD therapeutics market because of availability of these products present at a competitive price. The Omnitrope was approved by the US Food and Drug Administration (US FDA) after long delays and court proceedings.

Scope
The report provides information on the key drivers and challenges of the growth hormone deficiency therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) growth hormone deficiency therapeutics market revenue data for 2005–2010, and 2011–2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidate’s fall under the therapy classes such as immunomodulator, anti-CD3 antibody, oral Insulin analogue, GLP-1 receptor agonist, interleukin-1 inhibitor, ultra-long acting insulin analogue, ultra-fast-acting insulin analogue, Insulin analogue and ultra rapid-acting insulin analogue.
- Analysis of the current and future competition in the seven key countries of the growth hormone deficiency therapeutics market. LG Life Sciences, BioPartners GmbH, Roche Group, Pfizer, Novo Nordisk, Astrazeneca, Ascendis Pharma A/S, Ipsen S.A., EMD Serono, Inc., Theratechnologies Inc, Eli Lilly and Company and Ambrx, Inc.they are key market players, is covered in this section.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the growth hormone deficiency therapeutics market.
- Analysis of key recent licensing and partnership agreements in growth hormone deficiency therapeutics market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global growth hormone deficiency therapeutics market.
- Increase revenue through an understanding of the key trends, innovative products and technologies, market segments and companies likely to affect the global growth hormone deficiency therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global growth hormone deficiency therapeutics market landscape? – Identify, understand and capitalize.